Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer.
暂无分享，去创建一个
K. Polyak | A. Moore | Ping Wang | A. Ross | Z. Medarova | P. Pantazopoulos | V. Petkova | Byunghee Yoo | N. Barteneva | A. Tena | A. Kavishwar | D. Tabassum